- Home
- REAL vs CSTL Comparison
REAL vs CSTL Comparison
Compare REAL & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- CSTL
- Stock Information
- Founded
- REAL 2011
- CSTL 2007
- Country
- REAL United States
- CSTL United States
- Employees
- REAL N/A
- CSTL N/A
- Industry
- REAL Other Specialty Stores
- CSTL Medical Specialities
- Sector
- REAL Consumer Discretionary
- CSTL Health Care
- Exchange
- REAL Nasdaq
- CSTL Nasdaq
- Market Cap
- REAL 871.2M
- CSTL 697.9M
- IPO Year
- REAL 2019
- CSTL 2019
- Fundamental
- Price
- REAL $10.07
- CSTL $21.75
- Analyst Decision
- REAL Strong Buy
- CSTL Strong Buy
- Analyst Count
- REAL 5
- CSTL 6
- Target Price
- REAL $11.70
- CSTL $37.67
- AVG Volume (30 Days)
- REAL 4.1M
- CSTL 440.1K
- Earning Date
- REAL 11-03-2025
- CSTL 11-03-2025
- Dividend Yield
- REAL N/A
- CSTL N/A
- EPS Growth
- REAL N/A
- CSTL N/A
- EPS
- REAL N/A
- CSTL N/A
- Revenue
- REAL $636,971,000.00
- CSTL $346,269,000.00
- Revenue This Year
- REAL $14.27
- CSTL N/A
- Revenue Next Year
- REAL $9.94
- CSTL N/A
- P/E Ratio
- REAL N/A
- CSTL N/A
- Revenue Growth
- REAL 12.68
- CSTL 20.40
- 52 Week Low
- REAL $2.71
- CSTL $14.59
- 52 Week High
- REAL $11.38
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- REAL 77.50
- CSTL 50.97
- Support Level
- REAL $8.02
- CSTL $21.28
- Resistance Level
- REAL $10.35
- CSTL $24.74
- Average True Range (ATR)
- REAL 0.47
- CSTL 1.11
- MACD
- REAL 0.14
- CSTL -0.33
- Stochastic Oscillator
- REAL 90.82
- CSTL 14.57
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.